Free Trial
NASDAQ:MGTX

MeiraGTx Q2 2024 Earnings Report

MeiraGTx logo
$7.49 +0.05 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$7.48 -0.01 (-0.13%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.45
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$0.28 million
Expected Revenue
$16.38 million
Beat/Miss
Missed by -$16.10 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MeiraGTx Earnings Headlines

What Are Some Strategies to Help Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat